Differentiated thyroid carcinoma : treatment and clinical consequences of therapy
Hoftijzer, H.C.
Citation
Hoftijzer, H. C. (2011, May 12). Differentiated thyroid carcinoma : treatment and clinical consequences of therapy. Retrieved from
https://hdl.handle.net/1887/17641
Version: Corrected Publisher’s Version
License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from: https://hdl.handle.net/1887/17641
Note: To cite this publication please use the final published version (if
Differentiated Thyroid Carcinoma
treatment and clinical consequences of therapy
Hendrieke C. Hoftijzer
Differentiated Thyroid Carcinoma
treatment and clinical consequences of therapy
Lay out & Cover design: Pieter Vos
Printed by: Optima Grafi sche Vormgeving, Rotterdam ISBN 978-94-6169-032-6
This research was fi nancially supported by Bayer Healthcare B.V. Mijdrecht, the Netherlands ZonMw-AGIKO grant
Publication of this thesis was fi nancially supported by Bayer Healthcare B.V., Novo Nordisk B.V., Servier Nederland Farma B.V., Merck Sharp & Dohme B.V., Genzyme Europe B.V., AstraZeneca B.V., Ipsen Farmaceutica B.V., Novartis Pharma B.V., J.E.
Differentiated Thyroid Carcinoma
treatment and clinical consequences of therapy
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnifi cus prof.mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties te verdedigen op donderdag 12 mei 2011
klokke 15.00 uur door
Hendrieke Catherijn Hoftijzer geboren te Schiedam
in 1980
Promotiecommissie
Promotores Prof. Dr. J.W.A. Smit LUMC
Prof. Dr. J.A. Romijn LUMC
Copromotor Dr. E.P.M. van der Kleij-Corssmit LUMC
Overige leden Prof. Dr. T.P. Links UMCG
Prof. Dr. J. Kievit LUMC
Prof. Dr. J. Morreau LUMC
Prof. Dr. T.J. Visser Erasmus MC
Prof. Dr. J.H. Bolk LUMC
Contents
Chapter 1. General introduction 7
Chapter 2. Retinoic acid receptor and retinoid X receptor subtype expres- sion for the differential diagnosis of thyroid neoplasms 47 Chapter 3. Benefi cial effects of sorafenib on tumor progression, but not
on radioiodine uptake, in patients with differentiated thyroid carcinoma
63
Chapter 4. Sorafenib induced hypothyroidism is associated with increased
type 3 deiodination 83
Chapter 5. The type 2 deiodinase Thr92Ala polymorphism is not associ- ated with T4 dose in athyroid patients treated for differentiated thyroid carcinoma or patients with Hashimoto thyroiditis
93
Chapter 6. The type 2 deiodinase ORFa-Gly3Asp polymorphism infl u- ences the setpoint of the hypothalamus-pituitary-thyroid axis in patients treated for differentiated thyroid carcinoma
103
Chapter 7. The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density
117
Chapter 8. Thyroid hormone rather than TSH decreases bone turnover during hypothyroidism in athyroid patients with differentiated thyroid carcinoma
133
Chapter 9. Short term overt hypothyroidism induces discrete diastolic dys- function in patients treated for differentiated thyroid carcinoma 147 Chapter 10. Quality of life in cured patients with differentiated thyroid
carcinoma 161
Chapter 11. General discussion and summary 173
Chapter 12. Nederlandse samenvatting 197
Chapter 13. List of publications 213
Chapter 14. Curriculum vitae 217
